To Reach Unrestricted Services for Transgender Women (TRUST)
Primary Purpose
Transgender Women, Substance Abuse, Hiv
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Adapted SBIRT for transgender women
Sponsored by
About this trial
This is an interventional prevention trial for Transgender Women
Eligibility Criteria
Inclusion Criteria:
- Transgender woman over the age of 18
- HIV uninfected
- no current substance abuse use according to AUDIT and SBIRT criteria
Exclusion Criteria:
- HIV infected transgender woman
- evidence of hazardous alcohol or illicit drug use
Sites / Locations
- Florida International University
- University of Central FloridaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
SBIRT-A
INFO-C
Arm Description
The screening, brief intervention and referral to treatment (SBIRT) will be adapted and used as the intervention in the experimental arm
The INFO-C group is a time-matched comparison control where information will be provided on substance use and PrEP services in a non-SBIRT format via printed and audio-visual study material
Outcomes
Primary Outcome Measures
Number of participants with substance abuse
The rate of change of substance abuse incidence for both arms
Secondary Outcome Measures
Rate of Preexposure prophylaxis (PrEP) election
The rate of PrEP election (or new PrEP users) among study participants in both arms
Full Information
NCT ID
NCT03877497
First Posted
December 6, 2018
Last Updated
June 8, 2021
Sponsor
University of Central Florida
Collaborators
Florida International University
1. Study Identification
Unique Protocol Identification Number
NCT03877497
Brief Title
To Reach Unrestricted Services for Transgender Women
Acronym
TRUST
Official Title
To Reach Unrestricted Services for Transgender Women
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Unknown status
Study Start Date
September 19, 2019 (Actual)
Primary Completion Date
October 20, 2022 (Anticipated)
Study Completion Date
May 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Central Florida
Collaborators
Florida International University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Florida has the fifth largest transgender population in the United States. Transgender women, particularly those of color, in the southern part of Florida are a marginalized population who are impacted by co-morbidities of substance abuse and HIV in their communities. The overall objective of the study is to use a vetted adapted brief intervention to stem the development of substance abuse in at-risk transgender women, and thereby increase primary and secondary prevention methods such as routine HIV screening, uptake of pre-exposure prophylaxis (PrEP) and use of non-occupational post-exposure prophylaxis (nPEP).
Detailed Description
Background: Transgender women are disproportionally affected by substance abuse and HIV. Evidence-based interventions that can address both issues simultaneously may efficiently improve the overall health of transgender women and reduce burdensome health and societal costs associated with substance abuse and HIV. In South Florida, the majority of transgender women identify as Black or Latina, or transgender women of color (TWOC). TWOC are at highest risk for substance abuse and HIV acquisition, due to multiple external stressors arising as a consequence of being a gender minority, and also a racial/ethnic minority. Studies have demonstrated Screening, Brief Intervention, and Referral to Treatment (SBIRT) to be effective in mitigating development of substance use disorders (SUD) in other at-risk, marginalized populations. An adapted culturally-tailored SBIRT focused on linkage to substance use services and HIV pre- and post-exposure prophylaxis (PrEP and nPEP) may effectively reduce the odds of individuals in this special population developing a SUD and also facilitate their voluntary election of HIV screening and use of PrEP/nPEP for HIV prevention. Objectives: K99 -In preparation for the independent phase, the career development phase will include training in qualitative research methods and intervention development. R00 - In the independent phase, the study objectives will be to (a) use a mixed-methods approach to obtain formative data among 40 transgender women that will aid in adapting and developing an adapted culturally tailored SBIRT intervention (SBIRT-A), (b) pre-test and refine SBIRT-A in 15 transgender women based on formative work and, (c) pilot test SBIRT-A in a sample of 76 transgender to assess feasibility and acceptability. Pilot Design: Randomized trial among 76 adult (18 years or older) HIV uninfected transgender women at moderate risk for developing a substance use disorder who will be randomized to either SBIRT-A or the control condition (INFO-C). The INFO-C group will be a time-matched comparison control where information will be provided on substance use and PrEP services in a non-SBIRT format via printed and audio-visual study material. There will be a follow-up visit in three months to assess linkage, and barriers and facilitators to substance use services and PrEP/nPEP. Analysis: Bivariate difference tests (chi square and t-tests) will be used to test differences between SBIRT-A and INFO-C participants for the primary outcome measures (linkage to substance use services, PrEP, and nPEP) at the three-month visit. Multivariate binary logistic regressions (post- and pre-intervention) will be used to determine substance use as a predictor of (1) HIV/STI screening in the past three months and (2&3) PrEP and nPEP uptake in the past three months. Significance: Results derived from this study will help elucidate the relationship between substance use and HIV among transgender women, including TWOC, in South Florida, and will provide evidence for a larger study that can test the efficacy of SBIRT-A to reduce prevalence of substance abuse and HIV in this special population. The aims of this study are parallel to the NIH/National Institute on Drug Abuse (NIDA) strategic plan to decrease HIV/AIDS health disparities, prevent HIV transmission, and better understand the interaction of drug abuse and HIV/AIDS.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Transgender Women, Substance Abuse, Hiv
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
76 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
SBIRT-A
Arm Type
Experimental
Arm Description
The screening, brief intervention and referral to treatment (SBIRT) will be adapted and used as the intervention in the experimental arm
Arm Title
INFO-C
Arm Type
Active Comparator
Arm Description
The INFO-C group is a time-matched comparison control where information will be provided on substance use and PrEP services in a non-SBIRT format via printed and audio-visual study material
Intervention Type
Behavioral
Intervention Name(s)
Adapted SBIRT for transgender women
Intervention Description
Transgender women will be screened for substance use. Those at moderate risk or less will be randomized into the study into either the intervention arm (SBIRT-A) or the control arm (CONTROL-C). Those at higher risk will be ineligible for the study and referred for substance use treatment services
Primary Outcome Measure Information:
Title
Number of participants with substance abuse
Description
The rate of change of substance abuse incidence for both arms
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Rate of Preexposure prophylaxis (PrEP) election
Description
The rate of PrEP election (or new PrEP users) among study participants in both arms
Time Frame
6 months
10. Eligibility
Sex
Male
Gender Based
Yes
Gender Eligibility Description
Transgender women
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Transgender woman over the age of 18
HIV uninfected
no current substance abuse use according to AUDIT and SBIRT criteria
Exclusion Criteria:
HIV infected transgender woman
evidence of hazardous alcohol or illicit drug use
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elena Cyrus, PhD
Phone
4072661507
Email
elena.cyrus@ucf.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Eric Schrimshaw, PhD
Phone
407-266-1501
Email
Eric.Schrimshaw@ucf.edu <Eric.Schrimshaw@ucf.edu>;
Facility Information:
Facility Name
Florida International University
City
Miami
State/Province
Florida
ZIP/Postal Code
33199
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
University of Central Florida
City
Orlando
State/Province
Florida
ZIP/Postal Code
32827
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elena Cyrus, PhD
Phone
407-266-1125
Email
elena.cyrus@ucf.edu
First Name & Middle Initial & Last Name & Degree
Eric Schrimshaw, PhD
Phone
407-266-1501
Email
eric.schrimshaw@ucf.edu
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
To Reach Unrestricted Services for Transgender Women
We'll reach out to this number within 24 hrs